YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis
Advanced Science · 2024-04 · 11 (13)
DOI: 10.1002/advs.202307242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 21.01.2024. Verfasst von Jingyuan Wen und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Carcinoma, Hepatocellular, Liver Neoplasms, RNA-Binding Proteins. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, State Key Project on Infection Disease of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
N6‐methyladenosine (m 6 A) modification orchestrates cancer formation and progression by affecting the tumor microenvironment (TME). For hepatocellular carcinoma (HCC), immune evasion and angiogenesis are characteristic features of its TME. The role of YTH N6‐methyladenosine RNA binding protein 2 (YTHDF2), as an m 6 A reader, in regulating HCC TME are not fully understood. Herein, it is discovered that trimethylated histone H3 lysine 4 and H3 lysine 27 acetylation modification in the promoter region of YTHDF2 enhanced its expression in HCC, and upregulated YTHDF2 in HCC predicted a worse prognosis. Animal experiments demonstrated that Ythdf2 depletion inhibited spontaneous HCC formation, while its overexpression promoted xenografted HCC progression. Mechanistically, YTHDF2 recognized the m 6 A modification in the 5′‐untranslational region of ETS variant transcription factor 5 (ETV5) mRNA and recruited eukaryotic translation initiation factor 3 subunit B to facilitate its translation. Elevated ETV5 expression induced the transcription of programmed death ligand‐1 and vascular endothelial growth factor A, thereby promoting HCC immune evasion and angiogenesis. Targeting YTHDF2 via small interference RNA‐containing aptamer/liposomes successfully both inhibited HCC immune evasion and angiogenesis. Together, this findings reveal the potential application of YTHDF2 in HCC prognosis and targeted treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
- Clinical Medical Research Center of Hepatic Surgery at Hubei Province, Wuhan, 430030, China.
- Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
- National Engineering Research Center for Nanomedicine College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
- Key Laboratory of Organ Transplantation, Ministry of Education; Key Laboratory of Organ Transplantation, National Health Commission; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Science, Wuhan, 43…
ORCID-Profile: Bixiang Zhang
Förderung
- National Natural Science Foundation of China
- State Key Project on Infection Disease of China
- National Key Research and Development Program of China
- Major Technological Innovation Projects of Hubei Province
- Fundamental Research Funds for the Central Universities, HUST
Zitieren
APA
Wen, J., Xue, L., Wei, Y., Liang, J., Jia, W., Yong, T., Chu, L., Li, H., Han, S., Liao, J., Chen, Z., Liu, Y., Liu, Q., Ding, Z., Liang, H., Gan, L., Chen, X., Huang, Z., & Zhang, B. (2024). YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis. Advanced Science, 11(13). https://doi.org/10.1002/advs.202307242
Vancouver
Wen J, Xue L, Wei Y, Liang J, Jia W, Yong T, et al. YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis. Advanced Science. 2024;11(13). doi:10.1002/advs.202307242
BibTeX
@article{Wen2024,
author = {Wen, Jingyuan and Xue, Lin and Wei, Yi and Liang, Junnan and Jia, Wenlong and Yong, Tuying and Chu, Liang and Li, Han and Han, Shenqi and Liao, Jingyu and Chen, Zeyu and Liu, Yiyang and Liu, Qiumeng and Ding, Zeyang and Liang, Huifang and Gan, Lu and Chen, Xiaoping and Huang, Zhao and Zhang, Bixiang},
title = {YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {13},
doi = {10.1002/advs.202307242}
}
EUVIMED